Our clinical observations corroborate the recently described prognostic association between plasma IL-6/CRP and poor survival of ICI-treated melanoma patients,6,34 and they identify high tumor IL6 expression as a predictor of poor atezolizumab monotherapy outcome in RCC. This evidence concerns the gene IL6 and melanoma.